Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Saved in:
| Title: | Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV |
|---|---|
| Authors: | Merck & Co., Inc. |
| Source: | Business Wire (English). 06/29/2026. |
| Abstract: | Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the company’s new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir). In 2024, state ADAPs supported more than 250,000 people with HIV in the United States. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the company’s new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir). In 2024, state ADAPs supported more than 250,000 people with HIV in the United States. [ABSTRACT FROM PUBLISHER] |
|---|
